AMRN

Amarin

• PUBT·15h ago

  Amarin post hoc REDUCE-IT analysis says risk-weighted apoB better flags residual CV risk in statin-treated patients

• Benzinga·15h ago

  Amarin Announces New Data From A Post Hoc Analysis Of The REDUCE-IT Trial; Apolipoprotein B More Effectively Identified Individuals At Increased Residual Cardiovascular Risk

• TipRanks·05/15 10:30

  Amarin Shareholders Reject Dilution, Governance Proposals at AGM

• PUBT·05/15 10:18

  Amarin shareholders reject share issuance authorization at annual meeting

• TipRanks·05/01 00:59

  Amarin Earnings Call Signals Leaner, Global Growth

• PUBT·04/30 13:04

  Wi2Wi grants CEO 3.85 million stock options at $0.05 per share

• Reuters·04/29 21:38

  US Supreme Court hears patent case with potentially sweeping implications for generics

• Seeking Alpha·04/29 20:44

  Amarin expects $70M in operating expense savings by June 30, 2026 while targeting positive 2026 cash flow

• Reuters·04/29 11:22

  CORRECTED-Ireland's Amarin Q1 revenue rises 7% on higher international sales

• Benzinga·04/29 11:11

  Earnings Scheduled For April 29, 2026

• PUBT·04/29 11:10

  Amarin Q1 2026 net loss narrows 33% to $10.5 million; revenue rises 7% to $45.1 million

• Benzinga·04/29 11:04

  Amarin Corp Q1 Sales $45.132M Beat $43.771M Estimate

• Reuters·04/29 11:00

  AMARIN CORP: REITERATES EXPECTATION FOR FULL YEAR POSITIVE CASH FLOW

• Reuters·04/29 11:00

  CORRECTED-AMARIN Q1 PRODUCT REVENUE USD 43.3 MILLION (CORRECTS AMOUNT)

• Reuters·04/29 11:00

  AMARIN Q1 ADJ EPS $0.0